David G Warr
Overview
Explore the profile of David G Warr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chow R, Warr D, Navari R, Tsao M, Popovic M, Chiu L, et al.
Support Care Cancer
. 2018 May;
26(8):2519-2549.
PMID: 29796708
Purpose: Chemotherapy-induced nausea and vomiting (CINV) continues to be a common side effect of systemic anticancer therapy, decreasing quality of life and increasing resource utilization. The aim of this meta-analysis...
2.
Pezo R, Chen T, Berman H, Mulligan A, Razak A, Siu L, et al.
Breast Cancer Res Treat
. 2017 Nov;
168(1):159-168.
PMID: 29177603
Purpose: Next-generation sequencing (NGS) has identified recurrent genomic alterations in metastatic breast cancer (MBC); however, the clinical utility of incorporating routine sequencing to guide treatment decisions in this setting is...
3.
Jordan K, Warr D, Hinke A, Sun L, Hesketh P
Support Care Cancer
. 2015 Oct;
24(5):1941-1954.
PMID: 26476625
Purpose: This meta-analysis was performed to evaluate the efficacy of neurokinin-1 receptor antagonists (NK1RAs) for the prevention of chemotherapy-induced nausea and vomiting (CINV) across different categories of chemotherapeutic emetogenicity. Methods:...
4.
Popovic M, Warr D, DeAngelis C, Tsao M, Chan K, Poon M, et al.
Support Care Cancer
. 2014 Mar;
22(6):1685-97.
PMID: 24590374
Purpose: Palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT(3)RA) with a strong binding affinity and long half-life, has been used in numerous trials for the prophylaxis of chemotherapy-induced nausea and vomiting...
5.
Hesketh P, Warr D, Street J, Carides A
Support Care Cancer
. 2010 Jul;
19(9):1297-302.
PMID: 20623144
Background: Cisplatin-based highly emetogenic chemotherapy (HEC) displays a biphasic pattern of emesis with both an early and delayed period. In contrast, moderately emetogenic chemotherapy (MEC) has a monophasic pattern. The...
6.
Warr D, Street J, Carides A
Support Care Cancer
. 2010 May;
19(6):807-13.
PMID: 20461438
Goals Of Work: A number of prognostic factors have been identified as risk factors for chemotherapy-induced emesis. This post-hoc analysis addressed whether: (1) these prognostic factors can identify a low-risk...
7.
Leighl N, Dent S, Clemons M, Vandenberg T, Tozer R, Warr D, et al.
Breast Cancer Res Treat
. 2007 Apr;
108(1):87-92.
PMID: 17458693
Background: First- and second-line chemotherapy with anthracyclines and taxanes in metastatic breast cancer yield a modest improvement in survival with potentially significant toxicity. Subsequent lines of chemotherapy yield response rates...
8.
Dudgeon D, Bruera E, Gagnon B, Watanabe S, Allan S, Warr D, et al.
J Pain Symptom Manage
. 2007 Apr;
33(4):365-71.
PMID: 17397698
This multicenter trial examined the efficacy and safety of dextromethorphan (DM) as an enhancer of analgesia and modulator of opioid tolerance in cancer patients with pain. Eligible patients were randomized...
9.
Herrstedt J, Muss H, Warr D, Hesketh P, Eisenberg P, Raftopoulos H, et al.
Cancer
. 2005 Aug;
104(7):1548-55.
PMID: 16104039
Background: An aprepitant (APR) regimen was evaluated for prevention of nausea and emesis due to moderately emetogenic chemotherapy (MEC) over multiple cycles. Methods: The authors performed a randomized, double-blind study....
10.
Warr D, Grunberg S, Gralla R, Hesketh P, Roila F, de Wit R, et al.
Eur J Cancer
. 2005 Jun;
41(9):1278-85.
PMID: 15939263
In this work, data from two phase III studies were pooled to further evaluate the NK(1) antagonist aprepitant for prevention of cisplatin induced nausea and vomiting. One thousand and forty...